Publications:

A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.

International Journal Of Cancer

Bellmann, Lydia L; Cappellano, Giuseppe G; Schachtl-Riess, Johanna F JF; Prokopi, Anastasia A; Seretis, Athanasios A; Ortner, Daniela D; Tripp, Christoph H CH; Brinckerhoff, Constance E CE; Mullins, David W DW; Stoitzner, Patrizia P

Publication Date: 2020-03-01

Variant appearance in text: BRAF: H60c

PubMed Link: 31702822

Variant Present in the following documents:

• Main text
• IJC-146-1409.pdf

View BVdb publication page